Results 201 to 210 of about 80,877 (282)

Illicit drug supply, naloxone availability, and overdose mortality in the fentanyl era: a systematic review. [PDF]

Health Aff Sch
Khezri M, Holm J, Dahlen A, Johnson C, Agyabeng K, Lei F, Pagán JA, Healton C, Farhat T.   +8 more
europepmc   +1 more source

State legal innovations to encourage naloxone dispensing.

Journal of the American Pharmacists Association, 2017
C. Davis, Derek H Carr
semanticscholar   +1 more source

A mixed-methods evaluation of a statewide naloxone distribution project: considerations for future implementation of opioid overdose prevention initiatives. [PDF]

BMC Public Health
Beeler S, Golan O, Call A, Marino N, Ghobadi A, Monahan K.   +5 more
europepmc   +1 more source

Naloxone and Clinical Outcomes in Suspected Opioid-Associated Out-of-Hospital Cardiac Arrests.

JAMA Netw Open
Wang RC, Toy J, Montoy JCC, Tolles J, Ehlers PF, Donofrio-Odmann JJ, Menegazzi JJ, Gausche-Hill M, Rodriguez RM, Dillon DG, CAL-ROC Investigators.   +10 more
europepmc   +1 more source

Impact of virtual case conferences between primary care clinicians and an interdisciplinary chronic pain clinic. [PDF]

Can Fam Physician
Jorgenson DJ, Halpape K, Marwah R, Siton M.   +3 more
europepmc   +1 more source

Assessment of a County-Wide, Pan-First Responder Take-Home Naloxone Program in Denver, Colorado. [PDF]

J Am Coll Emerg Physicians Open
Jacoves J, Mannerings A, Stader D, Camacho MA, Neuenschwander J, Mason A, Petrasic K, Weiner SG.   +7 more
europepmc   +1 more source

The positivity rate of opioid drug urine testing in an emergency department between 2016 and 2024, before and after the introduction of fentanyl testing. [PDF]

Subst Abuse Treat Prev Policy
Miron O, Zeltser D, Schreiber S, Peles E.   +3 more
europepmc   +1 more source

Cost-effectiveness of community-based interventions for reducing opioid overdose and non-overdose deaths: simulation modeling of HEALing Communities Study. [PDF]

Lancet Reg Health Am
Chhatwal J, Sahinkoc M, Chen Q, Dowd W, Xiao J, Zarkin GA, Aldridge A, Barocas JA, Cerdá M, Fareed N, Frazier LA, Hyder A, Keyes KM, Knott CE, LaRochelle M, Linas BP, Oga E, Roberts SM, Samet JH, Schackman BR, Seiber EE, Starbird LE, Villani J, Knudsen AB, Barbosa C.   +24 more
europepmc   +1 more source

Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice. [PDF]

Psychopharmacology (Berl)
Watkins JM, Hahn R, Dempsey M, Hohmann AG.   +3 more
europepmc   +1 more source